Provided by Tiger Trade Technology Pte. Ltd.

Adaptive Biotechnologies Corp

28.35
+0.98003.58%
Post-market: 28.350.00000.00%19:47 EDT
Volume:1.58M
Turnover:44.41M
Market Cap:4.53B
PE:-68.93
High:28.41
Open:27.59
Low:27.31
Close:27.37
52wk High:29.96
52wk Low:12.00
Shares:159.76M
Float Shares:125.00M
Volume Ratio:0.55
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4113
EPS(LYR):-0.3922
ROE:-38.76%
ROA:-4.12%
PB:31.69
PE(LYR):-72.29

Loading ...

Adaptive Biotechnologies is Maintained at Buy by Guggenheim

Dow Jones
·
Jul 30

Adaptive Biotechnologies price target raised to $25 from $24 at BTIG

TIPRANKS
·
Jul 30

Adaptive Biotechnologies Corp : Morgan Stanley Raises Target Price to $22 from $20

THOMSON REUTERS
·
Jul 30

U.S. Research ROUNDUP-Equinix, Meta, S&P Global

Reuters
·
Jul 30

Adaptive Biotechnologies Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Jul 30

Adaptive Biotechnologies Q2 Net Loss Widens to $39.9 Million; Revenue Rises 22% to $71.6 Million

Reuters
·
Jul 30

Adaptive Biotechnologies Shares Drop 6.9% in Extended Trading After Posting Quarterly Results

THOMSON REUTERS
·
Jul 30

Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estimate

Benzinga Earnings
·
Jul 30

Adaptive Biotechnologies Q2 EPS USD -0.25

Reuters
·
Jul 30

Adaptive Biotechnologies Expects Fy2026 Mrd Revenue $268 Mln-$278 Mln

THOMSON REUTERS
·
Jul 30

Adaptive Biotechnologies Q2 Adjusted Ebitda USD -700 Thousand

THOMSON REUTERS
·
Jul 30

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Jul 30

Adaptive Biotechnologies CSO Harlan S. Robins Reports Disposal of Common Shares Worth $10.77 Million

Reuters
·
Jul 24

Is Adaptive Biotechnologies (ADPT) Fully Valued As Its Zacks Upgrade Lifts Earnings Hopes?

Simply Wall St.
·
Jul 23

Earning Preview: Adaptive Biotechnologies Corp Q2 revenue is expected to increase by 33.37%, and institutional views are predominantly bullish

Earnings Agent
·
Jul 23

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Disposes of 5,000 Shares for $115,000

Reuters
·
Jul 21

Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 105,762 Common Shares Worth $2.39 Million

Reuters
·
Jul 18

Adaptive Biotechnologies (ADPT) Stock Looks Reasonable On Cash Flow Yet Rich On Sales

Simply Wall St.
·
Jul 11

Adaptive Biotechnologies is Maintained at Equal-weight by Morgan Stanley

Dow Jones
·
Jul 10

Adaptive Biotechnologies price target raised to $20 from $18 at Morgan Stanley

TIPRANKS
·
Jul 09